Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Seagate Technology Holdings PLC (STX) Price & Performance

Mesoblast LimitedTrade
Seagate Technology Holdings PLCTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Seagate Technology Holdings PLC — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Seagate Technology Holdings PLC trades at $883.74 (market cap $185.97B). The key difference: Seagate Technology Holdings PLC is far larger — about 84.1× Mesoblast Limited's market cap, and Seagate Technology Holdings PLC pays a 0.36% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOSTX
Market Cap
$2.21B$185.97B
Sector
TechnologyTechnology
52-Week High
$20.96$1.09K
52-Week Low
$12.88$154.43
Enterprise Value
$2.21B$188.12B
Dividend Yield
0.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Seagate Technology Holdings PLC

Seagate Technology (STX) trades at $800.74, down 1.48% today, with a bearish technical signal but strong recent earnings beats driven by AI storage demand. The company reported Q2 2026 EPS of $5.71, beating expectations of $5.10, with revenue growth and margin expansion supported by its HAMR technology and data center contracts. However, high valuation ratios (P/E 59.03, P/S 15.41) and negative shareholder equity pose fundamental concerns.

The outlook is mixed: AI-driven demand and analyst bullishness (54.91% buy ratings) support upside to the $1,130 consensus target, but elevated valuation, legal settlements, and competitive pressures in the storage market present significant risks. Cash flow volatility and debt levels require monitoring for sustained growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Seagate Technology Holdings PLC

Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital

Read more on STX